Trend Watch

Bristol-Myers Squibb, Intercept Continue Support of NASH Study

Target PharmaSolutions announced that both Bristol-Myers Squibb and Intercept have extended their strategic partnerships for the ongoing TARGET-NASH study to a multi-year agreement, according to a company press releases.

TARGET-NASH is a longitudinal observational study of patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis designed to collect retrospective and prospective data for a biorepository that the company’s stakeholders can access for translational studies.

“We are developing valuable real-world data and insight on the NASH patient population. Our industry partners are benefitting from their participation in TARGET-NASH as each company works to enhance its understanding of this increasingly prevalent disease and to progress its NASH development program,” Meg Powell, CEO of Target PharmaSolutions, said in a press release. “We are excited to have the opportunity to assist our industry partners in these critical efforts.”

The TARGET-NASH investigators have so far enrolled 2,364 patients from 55 sites and plans to enroll a total of 15,000 patients over the coming years. The study is led by an academic committee chaired by Arun Sanyal, MD, from Virginia Commonwealth University, Ken Cusi, MD, from the University of Florida, and Brent Tetri, from St. Louis University.

Reference: www.targetpharmasolutions.com

Target PharmaSolutions announced that both Bristol-Myers Squibb and Intercept have extended their strategic partnerships for the ongoing TARGET-NASH study to a multi-year agreement, according to a company press releases.

TARGET-NASH is a longitudinal observational study of patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis designed to collect retrospective and prospective data for a biorepository that the company’s stakeholders can access for translational studies.

“We are developing valuable real-world data and insight on the NASH patient population. Our industry partners are benefitting from their participation in TARGET-NASH as each company works to enhance its understanding of this increasingly prevalent disease and to progress its NASH development program,” Meg Powell, CEO of Target PharmaSolutions, said in a press release. “We are excited to have the opportunity to assist our industry partners in these critical efforts.”

The TARGET-NASH investigators have so far enrolled 2,364 patients from 55 sites and plans to enroll a total of 15,000 patients over the coming years. The study is led by an academic committee chaired by Arun Sanyal, MD, from Virginia Commonwealth University, Ken Cusi, MD, from the University of Florida, and Brent Tetri, from St. Louis University.

Reference: www.targetpharmasolutions.com